Zelminemab

Zelminemab (AMG-301) is a humanized monoclonal antibody that inhibits PACAP type I (PAC1) receptor[1].

Product Specifications

CAS Number

[2225850-33-7]

Product Name Alternative

AMG-301

UNSPSC

12352203

Target

Adenylate Cyclase

Type

Inhibitory Antibodies

Related Pathways

GPCR/G Protein

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/zelminemab.html

Purity

99.0

Solubility

10 mM in DMSO

Smiles

[Zelminemab]

Molecular Weight

(145.22 kDa)

References & Citations

[1]Eloisa Rubio-Beltrán, et al. PACAP38 and PAC1 receptor blockade: a new target for headache? J Headache Pain. 2018 Aug 7;19 (1) :64. |[2]Hoffmann J, et al. PAC-1 receptor antibody modulates nociceptive trigeminal activity in rat. Cephalalgia. 2016;36 (1S) :141–141.